NCT01069328View on ClinicalTrials.gov

Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

September 30, 2011

Study Completion Date

October 31, 2011

Conditions
Carcinoma, Non-Small-Cell LungLung Cancer
Interventions
DRUG

Nexavar (Sorafenib, BAY43-9006)

Sorafenib 200 mg orally BID interrupted dosing

DRUG

Nexavar (Sorafenib, BAY43-9006)

Sorafenib 400 mg orally BID interrupted dosing

DRUG

Bevacizumab

Bevacizumab 2.5 mg/kg intravenously

DRUG

Bevacizumab

Bevacizumab 5 mg/kg intravenously

DRUG

Bevacizumab

Bevacizumab 7.5 mg/kg intravenously

DRUG

Bevacizumab

Bevacizumab 10 mg/kg intravenously

DRUG

Paclitaxel

Paclitaxel 200 mg/m² intravenously

DRUG

Carboplatin

Carboplatin AUC 6 intravenously

Trial Locations (2)

55905

Rochester

77030

Houston

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY